Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Ziopharm - Making Progress in Advanced Melanoma
Yahoo/Reuters
Monday, October 29, 2012 - 11:37am
tags:
melanoma, Ziopharm, Ad-RTS IL-12
2 Cancer-Based Biotech Firms With Great Upside Potential
Seeking Alpha
Monday, October 29, 2012 - 10:50am
tags:
Varian Medical, Galena Biopharma
GSK Chair Sir Christopher Gent is to step down in the next 2-3 years
Telegraph, UK
Monday, October 29, 2012 - 10:44am
tags:
GSK, Sir Christopher Gent
Bristol-Myers Squibb: Investors Can Focus On The Future After Plavix
Seeking Alpha
Monday, October 29, 2012 - 10:35am
tags:
Plavix, generics, Bristol-Myers Squibb
AstraZeneca May Not Be Immune To Patent Cliff But Dividend Is Solid
Seeking Alpha
Monday, October 29, 2012 - 10:35am
tags:
patent cliff, AstraZeneca, dividends
Shionogi to take 10 pct stake in GSK, Pfizer HIV drug venture
Reuters
Monday, October 29, 2012 - 10:32am
tags:
Shionogi, GSK, Pfizer, HIV, Dolutegravir
Impax Laboratories Earnings Are on Deck
Motley Fool
Monday, October 29, 2012 - 10:30am
tags:
Impax, earnings
Pfizer reschedules issuance of Q3 performance report, conference call
Yahoo/Fly on the Wall
Monday, October 29, 2012 - 10:29am
tags:
earnings, Pfizer
2012's Best Pharmaceutical Stock
Motley Fool
Sunday, October 28, 2012 - 11:50am
tags:
Novo Nordisk
Boss Pressure To Vote GOP Was Also Big Pharma Tactic In 2000
Forbes
Sunday, October 28, 2012 - 11:49am
tags:
Analysts Objectivity in Coverage of the Obesity Space
Motley Fool
Sunday, October 28, 2012 - 11:43am
tags:
obesity, weight loss, Orexigen, Arena Pharmaceuticals
Vertex Pharma Third Quarter Earnings Sneak Peek
Wall Street Cheat Street
Sunday, October 28, 2012 - 11:42am
tags:
Vertex Pharmaceuticals, earnings
A Looming Threat for Arena and VIVUS
Motley Fool
Sunday, October 28, 2012 - 11:41am
tags:
Arena Pharmaceuticals, Vivus, Orexigen, weight loss, obesity
Drug Shortage, Aging Baby Boomers Create A Great Opportunity For Teva
Seeking Alpha
Sunday, October 28, 2012 - 11:39am
tags:
Teva Pharmaceuticals
Eyeing a Sandbagged Guidance
Motley Fool
Sunday, October 28, 2012 - 11:37am
tags:
Regeneron
This Week in Biotech
Motley Fool
Sunday, October 28, 2012 - 11:37am
tags:
Columbia Laboratories, United Therapeutics, Watson Pharmaceuticals, Regeneron, Alexion
New Developments In Lipids To Watch Closely
Seeking Alpha
Sunday, October 28, 2012 - 11:31am
tags:
Lpath, Pfizer, iSONEP, Asonept, macular degeneration, multiple sclerosis, MS, Regeneron, Roche, Bayer, Sanofi, Valeant Pharmaceuticals, GSK
Agenus' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Seeking Alpha
Sunday, October 28, 2012 - 11:25am
tags:
Agenus, earnings
Forest Laboratories, Inc. Announces Settlement Agreement with Hetero Labs Ltd. in BYSTOLIC® Patent Litigation
Business Wire
Saturday, October 27, 2012 - 12:25pm
tags:
Forrest, Hetero Labs, Bystolic, generics, patents, lawsuits
Valeant Pharmaceuticals Price Target Lowered to $67.00 at Paradigm Capital (VRX)
Zolmax
Saturday, October 27, 2012 - 12:24pm
tags:
Valeant Pharmaceuticals

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.